Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06524882 · ClinicalTrials.gov registry record · Phase 3
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
A Phase 3 study of Amblyopia, sponsored by Jaeb Center for Health Research.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 252
- Enrollment target
- 20
- Study locations
NCT06524882 is a Phase 3 study of Amblyopia that is actively recruiting participants, run by Jaeb Center for Health Research. The registered enrollment target is 252 participants, above the 155-participant average among 24 other Amblyopia trials with a reported enrollment target (63% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT06524882, a Phase 3 study of Amblyopia, is actively recruiting participants, sponsored by Jaeb Center for Health Research.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 252 participants
- Enrollment target
- 20
- Study locations
Study Summary
Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinical assessments at 9- and 18-weeks post-randomization. At the 18-week primary outcome visit, participants who were randomly assigned to receive optical correction alone if needed with an IOD of 1 logMAR line (5 letters) or more, will be offered randomization to Luminopia or Vivid Vision dichoptic therapy and if they accept, followed forward with visits at 27- and 36-weeks post-randomization. The study will end for all other participants at 18 weeks.
Conditions Studied
Interventions
- DEVICE Luminopia
- DEVICE Vivid Vision
- DEVICE Optical Correction
Study Locations (20)
California
- University Eye Center at Ketchum Health - Anaheim
- Univ. of California- Berkeley - Berkeley
- Univ of California, Irvine- Gavin Herbert Eye Institute - Irvine
- Stanford University - Palo Alto
- Western University College of Optometry - Pomona
- University of California, Davis - Sacramento
- University of California San Francisco Department of Ophthalmology - San Francisco
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
- Illinois College of Optometry - Chicago
- Midwestern University Eye Institute - Downers Grove
- Progressive Eye Care - Lisle
Arizona
- Midwestern University Eye Institute - Glendale
- Phoenix Children's Medical Group - Ophthalmology - Scottsdale
- University of Arizona - Tucson
Arkansas
- Arkansas Childrens - Little Rock
- McFarland Eye Care Center - Little Rock
Florida
- Nova Southeastern University College of Optometry, The Eye Institute - Fort Lauderdale
- University of South Florida (USF) Eye - Tampa
Alabama
- UAB Pediatric Eye Care; Birmingham Health Care - Birmingham
Indiana
- Indiana School of Optometry - Bloomington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06524882
The ClinicalTrials.gov registry entry for NCT06524882 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 155-participant average among 24 other Amblyopia trials with a reported enrollment target (63% higher). The listed sponsor is Jaeb Center for Health Research, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amblyopia appearing as the primary indexed condition, and to 3 interventions - of which Luminopia is the first listed.
NCT06524882 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT06524882 about?
NCT06524882 is a clinical study titled "Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age". Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinic...
What is the current status of trial NCT06524882?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 252 participants. The study started on 2024-10-22. Estimated completion is 2027-11-01.
What conditions does trial NCT06524882 study?
This clinical trial studies the following conditions: Amblyopia.
What interventions are being tested in trial NCT06524882?
The interventions under investigation include: Luminopia (DEVICE), Vivid Vision (DEVICE), Optical Correction (DEVICE).
Who is sponsoring clinical trial NCT06524882?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06524882 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amblyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
RECRUITING · Phase 3
-
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
RECRUITING · Phase 3
-
Amblyopia (Lazy Eye) Treatment Study
COMPLETED · Phase 3
-
Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children
COMPLETED · Phase 3
-
Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old
COMPLETED · Phase 3
-
Trial Comparing Part-time Versus Full-time Patching for Severe Amblyopia
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.